Residual lesions, resolved disease: redefining response in metastatic renal cell carcinoma
The Lancet Medical Imaging & Theranostics · 2026
DOI: 10.1016/j.lanmit.2026.100014 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Lancet Medical Imaging & Theranostics, 2026. Verfasst von Serin Moghrabi und 1 weiteren Autor:innen. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
When a patient with metastatic renal cell carcinoma remains progression free for years on immunotherapy, but residual lesions persist on CT, clinicians face a fundamental question: does visible disease still represent viable cancer? The immunotherapy era has exposed a fundamental limitation: residual lesions often persist despite prolonged disease control, but radiology cannot distinguish viable tumours from fibrosis, necrosis, or immune remodelling. In The Lancet Medical Imaging & Theranostics, Chang Lei and colleagues1 ask whether a complete metabolic response on [18F] fluorodeoxyglucose ([18F]FDG)-PET–CT matters more than an anatomical complete response in patients receiving first-line immune checkpoint inhibitor-based therapy.
Zitieren
APA
Moghrabi, S., & Al-Ibraheem, A. (2026). Residual lesions, resolved disease: redefining response in metastatic renal cell carcinoma. The Lancet Medical Imaging & Theranostics. https://doi.org/10.1016/j.lanmit.2026.100014
Vancouver
Moghrabi S, Al-Ibraheem A. Residual lesions, resolved disease: redefining response in metastatic renal cell carcinoma. The Lancet Medical Imaging & Theranostics. 2026. doi:10.1016/j.lanmit.2026.100014
BibTeX
@article{Moghrabi2026,
author = {Moghrabi, Serin and Al-Ibraheem, Akram},
title = {Residual lesions, resolved disease: redefining response in metastatic renal cell carcinoma},
journal = {The Lancet Medical Imaging & Theranostics},
year = {2026},
doi = {10.1016/j.lanmit.2026.100014}
}
EUVIMED